Heidy King-Jones, the See Remarks of $SYRE, sold 400 shares of the company on 09-02-2026 for an estimated $36,000. We received data on the trade from a recent SEC filing. This was a sale of approximately 12.3% of their shares of this class of stock. Following this trade, they now own 2,845 shares of this class of $SYRE stock.
$SYRE Insider Trading Activity
$SYRE insiders have traded $SYRE stock on the open market 62 times in the past 6 months. Of those trades, 0 have been purchases and 62 have been sales.
Here’s a breakdown of recent trading of $SYRE stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT sold 4,684,781 shares for an estimated $399,658,667
- SHELDON SLOAN (Chief Medical Officer) has made 0 purchases and 11 sales selling 102,958 shares for an estimated $7,354,471.
- CAMERON TURTLE (Chief Executive Officer) has made 0 purchases and 23 sales selling 90,000 shares for an estimated $6,924,366.
- SCOTT L BURROWS (Chief Financial Officer) has made 0 purchases and 18 sales selling 83,232 shares for an estimated $6,760,769.
- HEIDY KING-JONES (See Remarks) has made 0 purchases and 5 sales selling 28,399 shares for an estimated $2,480,528.
- JEFFREY W. ALBERS has made 0 purchases and 3 sales selling 23,000 shares for an estimated $2,404,190.
- MICHAEL THOMAS HENDERSON sold 20,000 shares for an estimated $2,000,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SYRE Hedge Fund Activity
We have seen 184 institutional investors add shares of $SYRE stock to their portfolio, and 84 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 4,018,101 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $356,727,006
- PARADIGM BIOCAPITAL ADVISORS LP added 1,883,512 shares (+96.2%) to their portfolio in Q2 2026, for an estimated $167,218,195
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,722,300 shares (+inf%) to their portfolio in Q2 2026, for an estimated $152,905,794
- CAPITAL WORLD INVESTORS added 1,648,989 shares (+247.4%) to their portfolio in Q2 2026, for an estimated $146,397,243
- RA CAPITAL MANAGEMENT, L.P. removed 1,621,620 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $143,967,423
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,362,125 shares (+85.2%) to their portfolio in Q2 2026, for an estimated $120,929,457
- FMR LLC added 1,245,163 shares (+10.6%) to their portfolio in Q2 2026, for an estimated $110,545,571
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$SYRE Analyst Ratings
Wall Street analysts have issued reports on $SYRE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Deutsche Bank issued a "Buy" rating on 06/04/2026
To track analyst ratings and price targets for $SYRE, check out Quiver Quantitative's $SYRE forecast page.
$SYRE Price Targets
Multiple analysts have issued price targets for $SYRE recently. We have seen 11 analysts offer price targets for $SYRE in the last 6 months, with a median target of $95.0.
Here are some recent targets:
- David Hoang from Deutsche Bank set a target price of $135.0 on 06/23/2026
- Julian Harrison from BTIG set a target price of $112.0 on 06/15/2026
- Alex Thompson from Stifel set a target price of $107.0 on 05/06/2026
- Samantha Semenkow from Citigroup set a target price of $97.0 on 05/06/2026
- Debanjana Chatterjee from Jones Trading set a target price of $95.0 on 04/17/2026
- Yanan Zhu from Wells Fargo set a target price of $90.0 on 04/14/2026
- David Nierengarten from Wedbush set a target price of $80.0 on 04/14/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
